



Supplementary Figure S3: *in vivo* characterization of VEGFR-TKIs. A-C) 786-O tumor xenografts treated with cabozantinib (15, 30, 60 mg/kg; PO; QD), lenvatinib (5 and 10 mg/kg; PO; QD), or axitinib (15 and 30 mg/kg; PO; BID) for 21 days. Final tumor volume analyzed by one-way ANOVA following homogeneity of variance tests. Data represent mean ± S.E.M., n=8 mice per group (*p<0.05; **p<0.01). D-F) pPERK relative to total PERK were evaluated from tumors sampled following 21 days of treatment. ANOVA statistical analysis compared differences between protein abundance. Bars highlight significant differences between groups (*p<0.05; **p<0.01, ***p<0.001). G-I) Mouse body weights measured twice weekly across the course of treatment.